Publication details
Avanafil, nový inhibitor fosfodiesterázy 5 v léčbě erektilní dysfunkce
| Title in English | Avanafil, a new inhibitor of phosphodiesterase type 5 for the treatment of erectile dysfunction |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Field | Psychiatry, sexuology |
| Keywords | erectile dysfunction; phosphodiesterase 5 inhibitors; avanafil |
| Description | Erectile dysfunction (ED) affects more than 54% of Czech men aged 35-65 years. The vast majority of ED cases are secondary to vasculogenic disorders, including diabetes, and previous radical prostatectomy and neurological conditions. The ideal treatment of ED should be easy to administer, non invasive, painless and highly efficacious, with minimal side effects. The first-line treatment for males with ED consists of oral phosphodiesterase type 5 (PDE5) inhibitor therapy. Additional shortcomings of the current oral PDE5 inhibitors also include occasional ineffectiveness and limited spontaneity. Avanafil is highly potent PDE5 inhibitor and highly selective for PDE5. Phase III clinical trials suggests that avanafil is an effective and well tolerated therapy for ED of broad-spectrum etiology and severity. The improvement in sexual function and tolerability coupled with the rapid onset of action and durability of effect, make avanafil a viable tool for on demand treatment of ED. |